Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   3:59:59 PM EDT
508.30
+2.20 (+0.44%)
Products, Community

U.S. FDA Authorizes Monoclonal Antibodies For Treatment Of COVID-19

Published: 11/22/2020 00:55 GMT
Regeneron Pharmaceuticals Inc (REGN) - U.S. FDA Authorizes Monoclonal Antibodies for Treatment of Covid-19.
U.S. FDA - Issued Emergency Use Authorization for Casirivimab, Imdevimab to Be Administered Together for the Treatment of Mild to Moderate Covid-19.
U.S. FDA - Casirivimab and Imdevimab Must Be Administered Together by Intravenous (iv) Infusion.
U.S. FDA - Casirivimab and Imdevimab Are Not Authorized for Patients Who Are Hospitalized Due to Covid-19 Or Require Oxygen Therapy Due to Covid-19.
U.S. FDA - Benefit of Casirivimab and Imdevimab Treatment Has Not Been Shown in Patients Hospitalized Due to Covid-19.